Peptide Therapeutics intermediate
Pancreatic Cancer: Oligopeptide Research Reference
Most lethal common cancer (5-year survival ~12%). KRAS mutations (90%). Usually diagnosed late. Treatments: FOLFIRINOX, gemcitabine/nab-paclitaxel, olaparib ...
By Encyclopeptide Editorial | 1 min read
pancreatic-cancer peptide research
Overview
Most lethal common cancer (5-year survival ~12%). KRAS mutations (90%). Usually diagnosed late. Treatments: FOLFIRINOX, gemcitabine/nab-paclitaxel, olaparib …
Clinical Significance
This molecule has important therapeutic or diagnostic applications in clinical medicine.
References
- Encyclopeptide Database. “Pancreatic Cancer” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Pancreatic Cancer: Oligopeptide Research Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept